Delivery Order SPE2DB20D9127-SPE2DB24FPRF2

Award Date 8/22/24
Potential Completion Date 9/13/24
Potential Value $74K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order under the Defense Logistics Agency's (DLA) SPE2DB Indefinite Delivery Contract (IDC) valued at $499,999,999. The contract covers a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. The current...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $74,275.20 firm fixed-price delivery order covers the supply of Xolair 150 mg/1.2 ml powder vials to support the recurring medical needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA, which allows the agency to issue...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a $15,474.00 firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to supply Xolair 150 mg/1.2 ml powder vials. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) with DLA under the SPE2DB program, which allows the agency to issue delivery orders for a wide range of pharmaceutical products to support the medical supply needs of Department of Defense...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order issued by the Defense Logistics Agency (DLA) under the SPE2DB Indefinite Delivery Contract (IDC). The $74,275.20 firm fixed-price award is for the supply of Xolair 150 mg/1.2 ml powder vials, a specialized pharmaceutical product used for medical treatments. The IDC held by DMS Pharmaceutical Group Inc. is valued at $499,999,999 and covers a comprehensive range of branded and generic...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) as a delivery order under the DLA's SPE2DB Indefinite Delivery Contract (IDC) valued at $499,999,999. The award, valued at $98,364.00, is for the provision of Xolair 150 mg/mL syringes to support the medical supply needs of military healthcare facilities. As a key supplier in the federal pharmaceutical supply chain, DMS...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB indefinite delivery contract valued at up to $499,999,999. The contract is for the delivery of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical supplies, to support the recurring medical needs of military healthcare facilities worldwide. The specific product...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $3,094.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the supply of Xolair 150 mg/mL syringes to support the medical needs of military healthcare facilities. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The IDC...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $6,963.30 firm fixed-price delivery order is for the pharmaceutical product Xolair 150 mg/mL syringe. This award is part of DMS Pharmaceutical Group's larger $499,999,999 indefinite delivery contract (IDC) with the DLA to provide a wide range of pharmaceutical items, including both common and specialized medications, to support...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $9,671.25 firm fixed-price delivery order is for the pharmaceutical product XOLAIR 150 MG/ML SYRINGEML, with a completion date of June 4, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue delivery...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a Firm Fixed Price Delivery Order with a ceiling value of $7,737.00. The contract was awarded by the Defense Logistics Agency (DLA) to supply the pharmaceutical product Xolair 150 mg/1.2 ml powder for injection. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a wide range of medications and medical supplies to support the recurring medical needs...
  • SPE2DB20D9127
    Indefinite Delivery Contract
  • SPE2DB20D9127-SPE2DB24FPRF2
    Delivery Order

This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order valued at $74,275.20 issued under the Defense Logistics Agency's (DLA) SPE2DB Indefinite Delivery Contract. The contract is for the provision of pharmaceutical products, including Xolair 150 mg/1.2 ml powder, to support the medical supply needs of military healthcare facilities. This single-award IDC, valued at $499,999,999, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, positioning DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain. The contract does not have a set-aside designation, allowing the company to leverage its woman-owned small business status to secure direct federal awards across multiple product categories and medical domains.

Generated 2/27/25, 11:50 AM